Maternal oxygen desaturation with intravenous magnesium therapy

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Pharmacology

Background:

• Magnesium sulfate is frequently used to prevent preterm birth and manage preeclampsia.
• Maternal oxygen desaturation is a potential adverse effect of magnesium sulfate therapy.
• Understanding the incidence and risk factors for desaturation is crucial for patient safety.

Purpose of the Study:

• To investigate the occurrence, treatment, and outcomes of maternal oxygen desaturation during magnesium sulfate therapy.
• To assess the impact of phenobarbital co-administration on oxygen saturation.
• To identify factors associated with maternal oxygen desaturation.

Main Methods:

• Post hoc analysis of a randomized double-blind trial involving mothers at risk for preterm delivery.
• Subset of patients received intravenous magnesium sulfate with either phenobarbital or placebo.
• Maternal oxygen saturation was monitored using pulse oximetry.

Main Results:

• Maternal oxygen desaturation (SpO2 < 90%) occurred in 11% of women in both placebo and magnesium sulfate groups.
• No significant differences in lowest oxygen saturation, magnesium levels, or fetal outcomes were observed between groups.
• Multiple gestation was the only independent variable associated with lower maternal oxygen saturation.

Conclusions:

• Maternal oxygen desaturation is a common event during intravenous magnesium sulfate therapy.
• Simultaneous phenobarbital administration does not increase the frequency of desaturation.
• Multiple gestation may be linked to reduced maternal oxygen saturation, but overall maternal and fetal status remain stable.